MPL突变相关家族性血小板增多症的临床病程:64例儿童与成人患者回顾性综述
该研究回顾性分析了2013年3月至2021年2月诊治的64例MPL突变相关家族性血小板增多症患者,其中26例(41%)为儿童,38例(59%)为成人,诊断中位年龄20岁。60例(94%)血小板增多,21例(33%)用阿司匹林、7例(11%)用羟基脲,63例(98%)无血栓或出血事件,未发现MPL突变与血栓或出血显著相关。
要点
- MPL突变相关家族性血小板增多症患者血栓和出血事件罕见,98%无事件。
- 94%患者表现血小板增多,仅1例JAK2突变阳性。
- 阿司匹林和羟基脲使用率分别为33%和11%,无显著血栓出血关联。
核心结论
- MPL突变相关家族性血小板增多症患者血栓或出血事件发生率低,未发现显著关联。
研究设计与样本
- 回顾性综述,纳入2013年3月至2021年2月诊治的64例MPL相关家族性血小板增多症儿童和成人患者。
主要发现
- 60例(94%)血常规显示血小板增多,52例接受额外基因检测,仅1例JAK2突变阳性。
- 21例(33%)处方阿司匹林,7例(11%)处方羟基脲,63例(98%)未发生血栓或出血事件。
关键数值与推荐
- 血小板增多患者60例(94%),JAK2突变阳性1例。
- 阿司匹林使用21例(33%),羟基脲使用7例(11%),无血栓出血事件63例(98%)。
临床怎么用
- MPL相关家族性血小板增多症患者血栓出血风险低,治疗决策需权衡获益与风险。
局限性
- 回顾性设计,样本量64例,来自特定部落人群,结论外推需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Familial thrombocytosis (FT) is a rare hereditary haematological disorder characterised by increased platelet count, usually caused by germ-line mutations in thrombopoietin (THPO), myeloproliferative leukaemia virus oncogene (MPL) or Janus kinase 2 (JAK2) genes, and can be associated with increased risk of thrombosis. We aimed to determine the yield of diagnostic tests, assess treatment received and describe the clinical course of MPL-associated FT. We retrospectively reviewed all paediatric and adult haematology patients diagnosed with MPL-related FT, who were seen in our clinics from March 2013 to February 2021. Of 64 eligible patients, 26 (41%) were aged <14 years, while the remaining 38 (59%) patients were adults. The median (interquartile range) age at diagnosis was 20 (33·5) years. In all, 26 tribes were represented in this cohort of 64 patients, out of which 31 (48%) patients belonged to two tribes. A total of 60 patients (94%) had thrombocytosis on blood count. Additional genetic tests, including myelodysplastic syndrome (MDS) gene panel, Philadelphia gene breakpoint cluster region-Abelson (BCR-ABL) and JAK2, were carried out for 52 patients and only one patient was positive for JAK2 mutation. In all, 21 (33%) patients were prescribed aspirin and seven (11%) were prescribed hydroxyurea. Overall, 63 (98%) patients did not develop any thrombotic or haemorrhagic event. There was no significant association of MPL-mutated FT with thrombosis or haemorrhage.
引用
- Al-Harbi T, Al-Zahrani M, Al-Balwi M, et al. Clinical course of myeloproliferative leukaemia virus oncogene (MPL) mutation-associated familial thrombocytosis: a review of 64 paediatric and adult patients. Br J Haematol. 2021. PMID: 34131895. doi:10.1111/bjh.17624
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。